REMINDER: Our user survey closes on Friday, please submit your responses here.
https://www.evaluate.com/vantage/articles/news/deals-snippets/csl-stops-short-buying-arcturus
Completely as a side issue and linking Arcturus Therapeutics with Arcturis Data is tenuous at best on just the basis of similarity of name. . One wonders why Though CSL held off buying outright. . Arcturus have also been on Merck’s radar
https://www.gurufocus.com/news/1540025/biogen-mirati-and-arcturus-reportedly-on-mercks-radar
There has too been no comment anywhere by Huma about their acquisition from Arcturis, only the statement, on what’s left of the Sensyne website. Financial details of this deal maybe interesting.
By the way the rebranded Co could still have its own identity within a ‘group’ after a buy out. Think jigsaw.
Their main accounts are now 3 weeks late at Companies House too. At Companies House the divisional accounts were issued up to Apr 21. With statements included dated Sep 22 from a board meeting. Due diligence or what.
That may well be the case. But why hold back. There has been no release of rebranding other than the new website. There has to be more as the website suggests. My view is the the rebranding is all part of a much bigger picture. Time will tell.
Good luck to those who held on here. Whatever the route is to get out of this unlisted situation, I believe we could be close to finding out. My gut feeling is still some kind of buy out by a listed Co that could involve a share deal. This would allow all major shareholders to continue to benefit from future activities. Still no real news from the Co directly, so I guess it’s ‘watch this space ‘ for the moment.
That’s a very healthy client base for Phesi. According to info contained in published accounts. The Phesi collaboration is for at least 7 years and the Co put in around 10 M into Phesi
https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
Phesi have had a little makeover of their website https://www.phesi.com/
Very similar in style to Arcturis Data. All info available points to their collaboration on the synthetic arm project.
I think there could be quite a lot to come once Arcturis fully update their website.
I would not rule out an offer that involves stock in the acquiring Co. It would be a great way to satisfy NHS holders and others. It would allow to be involved in the long term growth potential. I have already pointed out who that could be but it’s just a wild guess. There are many reasons why they would be a good fit and have just secured huge investment.
Backed by AstraZeneca, Huma are obviously adding to their digital health portfolio with the acquisition from Sensyne as per Sensyne Health website.
Some info on Huma
https://www.prnewswire.com/news-releases/huma-and-astrazeneca-partner-to-accelerate-innovation-for-digital-first-patient-care-301507043.html
Hopefully some cash now in the coffers to pay down a little of the loan notes and or cash for working capital.
And here we have it …. Divestment to Huma
https://www.sensynehealth.com/
What could be interesting is the new website identifies that the RWD business is held within Arcturis Data (UK) Ltd. Accounts to April 21, show that division had a loss of 20M with liabilities of around 30M. There is still Arcturis Holdings Ltd that accounts ending April 21, show a profit after tax of almost 21M and net assets of 82M. Perhaps this is what has been earmarked for divestment.
A fair bit of news to come I think.
Hopefully we can expect some shareholder update.
Watch out for Full website coming soon … it says
Here is the new website.
https://www.arcturisdata.com/
You are welcome.
Hopefully Alex Snow has been busy reorganising and realigning towards RWD and RWE which could attract some attention.
https://www.biopharmadive.com/spons/crossing-the-new-real-world-data-landscape/636210/
You could contact their Registrars, Equiniti, located in Lancing, West Sussex. They should be able to advise regarding share certificates.
Exactly. News can’t be too far away. Accounts too are delayed at Companies House. Awaiting accompanying announcement maybe.
You should call your broker